Epidemiology and characteristics of urinary tract dysfunction in multiple sclerosis patients

Introduction. Data on the epidemiology and nature of neurogenic lower urinary tract dysfunction (NLUTD) in multiple sclerosis (MS) are contradictory: the prevalence rate ranges from 50 to 90% according to different authors.

Purpose of the study. To assess the frequency and nature of urination disorders in patients with various forms of multiple sclerosis.

Materials and methods. We analyzed the data of patients observed in the Regional Centre of Multiple sclerosis at Sverdlovsk Regional Clinical Hospital No. 1. The study included 160 patients aged 42.6±12.3 years, of which 64% were men and 36% were women. The primary progressive course of the disease occurred in 5% of patients, the secondary progressive course in 39%, and remitting in 56%. The average score according to the Expanded Disability Status Scale (EDSS) was 3.94±2.10. The nature of neurogenic dysfunction of the lower urinary tract was evaluated using questionnaires (NBSS, SF-Qualiveen) and urodynamic studies.

Results. NLUTD were detected in 65% of MS patients. The average score according to the Neurogenic Bladder Symptom Scale (NBSS) in patients with NLUTD was 26.93±13.12, which was significantly (p < 0.001) exceed than the value of this indicator among patients without pelvic disorders (6.43±2.34). Symptoms of emptying were noted in more than half of patients with a neurogenic bladder in the presence of multiple sclerosis: poor urine flow (63%), abdominal straining during urination (76%). Complaints of storage symptoms, such as urgency and frequency, were presented by 98% of patients with neurogenic lower urinary tract dysfunction. Urinary incontinence was diagnosed in 84% of cases. The values of the «incontinence», «storage and voiding» and «complications» domains of NBSS were 8.66±7.17, 12.18±3.7 and 3.48±4.21, respectively. The total score of SF-Qaliveen questionnaire in patients with MS with urinary disorders was 2.93±1.13, in patients without NLUTD, 1.03±0.91 (р < 0,001).

Conclusions. Neurogenic lower urinary tract dysfunction occurs in patients with multiple sclerosis with a frequency of 65%. These urinary disorders have a significant impact on the patients` quality of life.

1. Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019;26(1):27‒40. https://doi.org/10.1111/ene.13819

2. Boyko A, Melnikov M. Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies. Brain Sci. 2020;10(5):E305. Published 2020 May 18. https://doi.org/10.3390/brainsci10050305

3. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol. 2018;31(6):752–759. https://www.doi.org/10.1097/WCO.0000000000000622

4. Sakakibara R. Neurogenic lower urinary tract dysfunction in multiple sclerosis, neuromyelitis optica, and related disorders. Clin Auton Res. 2019;29(3):313–320. https://doi.org/10.1007/s10286-018-0551-x

5. Autoimmunnye zabolevanija v nevrologii: klinicheskoe rukovodstvo. V 2 tomah. Pod red. I.A. Zavalishina, M.A. Piradova, A.N. Bojko, S.S. Nikitina, N.N. Spirina, A.V. Peresedovoj. Moskva: ROOI «Zdorov’e cheloveka», 2014. (in Russ.).

6. Pazhigova Z.B., Karpov S.M., Shevchenko P.P., Kashyrin A.I. Clinical neurological patients with multiple sclerosis in view of the state of gravity. Fundamental research. 2014;(7): 771‒775. (in Russ.). eLIBRARY ID: 21952310.

7. Shmidt T.E., Jahno N.N. Rassejannyj skleroz: rukovodstvo dlja vrachej. 5-e izd. Moskva: MEDpress-inform, 2016. (in Russ.). ISBN 978-5-00030-337-5

8. Philippova E.S., Bazhenov I.V., Volkova L.I., Moskvina E.Y., Turova E.L., Popova Y.V. Russian version of the neurogenic bladder symptom score (NBSS). Urologiia. 2018;(6):5‒13. (in Russ.). https://dx.doi.org/10.18565/urology.2018.6.5-13

9. Santos M, Sousa C, Pereira M, Pereira MG. Quality of life in patients with multiple sclerosis: A study with patients and caregivers. Disabil Health J. 2019;12(4):628–634. https://doi.org/10.1016/j.dhjo.2019.03.007

10. Clark R, Welk B. Patient reported outcome measures in neurogenic bladder. Transl Androl Urol. 2016;5(1):22‒30. https://doi.org/10.3978/j.issn.2223-4683.2015.12.05

11. Philippova E.S., Bazhenov I.V., Zyryanov A.V., Borzunov I.V., Moskvina E.Y., Morozova A.A., Buksman A.I. The urinaryspecific quality of life in multiple sclerosis patients: russian translation and validation of the SF-Qualiveen. Ural Medical Journal. (in Russ.). 2019;3(171):39‒43. https://doi.org/10.25694/URMJ.2019.03.19

12. Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, Karsenty G, Kessler TM, Schneider M, ‘t Hoen L, Blok B. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur Urol. 2016;69(2):324‒333. https://dx.doi.org/10.1016/j.eururo.2015.07.071

13. Tornic J, Panicker JN. The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Curr Neurol Neurosci Rep. 2018;18(8):54. Published 2018 Jun 28. https://doi.org/10.1007/s11910-018-0857-z

14. Bonniaud V, Parratte B, Amarenco G, Jackowski D, Didier JP, Guyatt G. Measuring quality of life in multiple sclerosis patients with urinary disorders using the Qualiveen questionnaire. Arch Phys Med Rehabil. 2004;85(8):1317‒1323. https://dx.doi.org/10.1016/j.apmr.2003.09.029

15. de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B; GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13(7):915‒928. https://dx.doi.org/10.1177/1352458506075651

16. Solaro C, Gamberini G, Masuccio FG. Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment. CNS Drugs. 2018;32(2):117‐133. https://doi.org/10.1007/s40263-018-0489-5